


AZD7624

Cat. No.:	HY-103672		
CAS No.:	1095004-78-6		
Molecular Formula:	C ₂₇ H ₃₀ FN ₅ O ₃		
Molecular Weight:	491.56		
Target:	p38 MAPK; Autophagy		
Pathway:	MAPK/ERK Pathway; Autophagy		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (127.15 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.0343 mL	10.1717 mL	20.3434 mL
		5 mM		0.4069 mL	2.0343 mL	4.0687 mL
10 mM			0.2034 mL	1.0172 mL	2.0343 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.23 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.23 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	AZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity.
IC ₅₀ & Target	p38 ^[1]
In Vitro	AZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity. AZD7624 inhibits LPS-induced TNFα in human mononuclear cells, in whole blood as well as in alveolar macrophages in vitro, with pIC ₅₀ s of 8.4, 8.1, and 9.0 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pehrson R, et al. AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNF α with Minimal Systemic Exposure. J Pharmacol Exp Ther. 2018 Jun;365(3):567-572.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA